Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC Presbyterian to Problematic Gram-Negative Organisms
Information source: University of Pittsburgh
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Gram Negative Organism
Phase: N/A
Status: Recruiting
Sponsored by: University of Pittsburgh Official(s) and/or principal investigator(s):
Brian Potoski, Pharm D, Principal Investigator, Affiliation: University of Pittsburgh
Overall contact:
Brian Potoski, Pharm D, Phone: 412-648-6401, Email: potoskiba@upmc.edu
Summary
The isolate samples will be collected over a period of one year once IRB approval has been
obtained. These isolates were collected as part of the patient's clinical care and once all
clinical testing is complete, all isolates will be discarded. The honest broker of our area
will collect the isolates and deidentify all information once all clinical testing is
complete. The isolates will be obtained from the microbiology lab.
Clinical Details
Official title: Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC Presbyterian to Problematic Gram-Negative Organisms
Study design: Cohort, Prospective
Detailed description:
The study will collect two hundred pseudomonas and 20 acinetobacter baumanti consecutive
bacterial isolates from microbiology. These isolates are collected as part of the patient's
clinical care and are discarded once all clinical testing is complete. The honest broker
will obtain these samples after all clinical testing is complete. All isolates will be
deidentified. These isolates will be tested using standardized susceptibility methods for
meropenem and imipenem. The activity of doripenem, a carbapenem currently being studied, and
arbekacin an aminoglycoside, will also be tested. The honest broker will also collect
limited patient data including underlying condition, presence of a solid organ transplant,
ward location, and antibiotic history over the three months prior to organism isolation. For
resistant isolates found, analytical and molecular techniques will be performed to determine
the mechanisms of resistance and whether resistant isolates are coming from a single
source/being transmitted from person to person.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Samples" for the purpose of this study are Gram negative bacteria in a Petri dish of
growth media.
Locations and Contacts
Brian Potoski, Pharm D, Phone: 412-648-6401, Email: potoskiba@upmc.edu
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, United States; Recruiting
Brian Potoski, Pharm D, Phone: 412-648-6401, Email: potoskiba@upmc.edu
Diana Lynn Pakstis, RN, BSN, Phone: 412-648-6553, Email: pakstisdl@dom.pitt.edu
Brian Potoski, Pharm D, Principal Investigator
Additional Information
Starting date: February 2007
Last updated: April 7, 2009
|
